IV.c

Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)

(Fr: bronchiolite oblitérante). Pattern distinct from BOOP or AFOP (See section I). It is suspected when airflow obstruction is noted in the context of normal or hyperlucent lungs on chest radiographs and a mosaic or (less often) a tree-in-bud pattern on HRCT studies. HSCT and lung transplant recipients and victims of exposure to noxious gases including chlorine are prone to the development of this complicaton. PMID 20371529, 20441501, 20477273. See under pathology, as bronchiolitis is as the name implies a designation used in pathology

Last update : 01/01/1970
 

Causative drugs

26

Chemicals

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.j I - Interstitial/parenchymal lung disease
I.j - Exogenous lipoid pneumonia (subacute, acute)
I.af I - Interstitial/parenchymal lung disease
I.af - Chemical (toxic) pneumonitis
II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH)
III.b III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.b - Pneumorenal syndrome (w/wo ANCAs)
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)
IV.n IV - Airway involvement
IV.n - Obstructive airway dysfunction (see also IVc, XVx)
IV.q IV - Airway involvement
IV.q - Reactive airway dysfunction syndrome (RADS)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (May commpany ILDs)
VIII.c VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma
VIII.h VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.h - Vocal cord dysfunction, adduction, closure, injury
X.m X - Systemic/Distant conditions, syndromes and reactions
X.m - Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)
X.u X - Systemic/Distant conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
X.ac X - Systemic/Distant conditions, syndromes and reactions
X.ac - Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS)
XI.s XI - Miscellaneous
XI.s - Sniffing death - Death from inhalation of compound
XII.m XII - Cardiovascular involvement / toxicity
XII.m - Cardiac- cardiorespiratory/pulmonary arrest
XIV.a XIV - Hemoglobinopathies - Abnormal hemoglobin states (acquired)
XIV.a - Methemoglobinemia
XIV.b XIV - Hemoglobinopathies - Abnormal hemoglobin states (acquired)
XIV.b - Sulfhemoglobinemia
XV.x XV - Pathology
XV.x - Path: Acute/subacute bronchiolitis (see also IVc, IVi)
XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)
XVII.p XVII - Infections & related conditions
XVII.p - Lung abscess/abscesses (see also VIr)
3

Crack cocaine

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
II.j II - Pulmonary edema - Acute lung injury - ARDS
II.j - Transient pulmonary opacities/infiltrates (see also under Iav)
III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)
IV.e IV - Airway involvement
IV.e - Cough (acute, violent, explosive)
IV.f IV - Airway involvement
IV.f - Severe or catastrophic bronchospasm or asthma attack (can be fatal)
V.b V - Pleural and/or pericardial involvement
V.b - Eosinophilic pleural effusion
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
V.x V - Pleural and/or pericardial involvement
V.x - Black pleural effusion
VI.a VI - Pulmonary vasculopathies
VI.a - Pulmonary embolism - Venous thrombosis/thromboembolism
VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum
VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death)
VIII.d VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.d - Thermal (burns, frostbite), chemical or caustic facial and/or airway injury
VIII.m VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.m - Drug foreign body in the airway
VIII.ac VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.ac - Retropharyngeal emphysema
VIII.ap VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.ap - Airway foreign body
X.ac X - Systemic/Distant conditions, syndromes and reactions
X.ac - Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS)
XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent
XI.c XI - Miscellaneous
XI.c - Pleuritic chest pain
XI.bp XI - Miscellaneous
XI.bp - Lung herniation
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.aa XII - Cardiovascular involvement / toxicity
XII.aa - Arterial (aorta, limb) vasoconstriction and/or ischemia, acute
XII.ae XII - Cardiovascular involvement / toxicity
XII.ae - Aortic dissection
XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.g XV - Pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa)
XV.q XV - Pathology
XV.q - Path: Foreign body deposits/granulomatous reaction
XV.s XV - Pathology
XV.s - Path: Pneumoconiosis (silicosis, talcosis, talcoma)
XV.bb XV - Pathology
XV.bb - Path: Airway inflammation
XV.bj XV - Pathology
XV.bj - Path: Alveolar carbonaceous material or deposits
XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing
XVI.d XVI - Imaging
XVI.d - Imaging: Alveolar opacities or haze with a batwing or butterfly distribution
XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation
XVIII.l XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.l - Eye catcher: Candy-cane esophagus
1

Fluorouracil (5-FU)

I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.d II - Pulmonary edema - Acute lung injury - ARDS
II.d - Pulmonary edema, cardiogenic
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)
IV.n IV - Airway involvement
IV.n - Obstructive airway dysfunction (see also IVc, XVx)
X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal)
XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade)
XII.e XII - Cardiovascular involvement / toxicity
XII.e - Takotsubo (stress) cardiomyopathy
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.m XII - Cardiovascular involvement / toxicity
XII.m - Cardiac- cardiorespiratory/pulmonary arrest
XII.w XII - Cardiovascular involvement / toxicity
XII.w - Asystole
XII.af XII - Cardiovascular involvement / toxicity
XII.af - Coronary vasospasm - Vasospastic angina
XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity
XV.z XV - Pathology
XV.z - Path: Obliterative (constrictive) bronchiolitis (see also IVc, IVn)
1

Herbals - Dietary botanical therapy - Health products/food - Plants

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
II.q II - Pulmonary edema - Acute lung injury - ARDS
II.q - Respiratory distress or failure, not otherwise specified
III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH)
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)
V.u V - Pleural and/or pericardial involvement
V.u - Eosinophilic pleuritis
VI.a VI - Pulmonary vasculopathies
VI.a - Pulmonary embolism - Venous thrombosis/thromboembolism
VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension
VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death)
VIII.c VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma
VIII.w VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.w - Uvulitis, uvular edema
IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)
IX.d IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.d - Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis)
X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal)
X.u X - Systemic/Distant conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
X.w X - Systemic/Distant conditions, syndromes and reactions
X.w - Eosinophilia myalgia syndrome (EMS)
XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent
XI.h XI - Miscellaneous
XI.h - Esophageal pathology (erosion, ulcer, tear, rupture, fistula)
XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning
XI.bi XI - Miscellaneous
XI.bi - Cyanide poisoning
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis (can be fulminant)
XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic)
XII.h XII - Cardiovascular involvement / toxicity
XII.h - Eosinophilic myocarditis
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.m XII - Cardiovascular involvement / toxicity
XII.m - Cardiac- cardiorespiratory/pulmonary arrest
XII.n XII - Cardiovascular involvement / toxicity
XII.n - Cardiovascular collapse - Cardiogenic shock - Hypotension
XII.r XII - Cardiovascular involvement / toxicity
XII.r - Heart failure (biventricular, congestive)
XII.w XII - Cardiovascular involvement / toxicity
XII.w - Asystole
XII.ag XII - Cardiovascular involvement / toxicity
XII.ag - Bradycardia
XII.ah XII - Cardiovascular involvement / toxicity
XII.ah - Tachycardia
XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.z XV - Pathology
XV.z - Path: Obliterative (constrictive) bronchiolitis (see also IVc, IVn)
XIX.d XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.d - BAL: Gross or microscopic bleeding/hemorrhage
XXIV.i XXIV - Veterinary medicine
XXIV.i - Veterinary: Respiratory/Ventilatory depression
XXIV.j XXIV - Veterinary medicine
XXIV.j - Veterinary: Cardiotoxicity
3

Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.u I - Interstitial/parenchymal lung disease
I.u - Relapsing or migrating pneumonitis/pneumonia (see also Id)
I.v I - Interstitial/parenchymal lung disease
I.v - Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
I.aa I - Interstitial/parenchymal lung disease
I.aa - Delayed ILD, -pneumonitis, -fibrosis
I.ad I - Interstitial/parenchymal lung disease
I.ad - Radiation recall pneumonitis
I.aj I - Interstitial/parenchymal lung disease
I.aj - Shrinking lung syndrome
I.ax I - Interstitial/parenchymal lung disease
I.ax - Chronic pneumonitis
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
II.d II - Pulmonary edema - Acute lung injury - ARDS
II.d - Pulmonary edema, cardiogenic
III.m III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.m - Coagulopathy
IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)
IV.n IV - Airway involvement
IV.n - Obstructive airway dysfunction (see also IVc, XVx)
IV.y IV - Airway involvement
IV.y - Eosinophilic airway disease (asthma, bronchitis, bronchiolitis)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (May commpany ILDs)
V.s V - Pleural and/or pericardial involvement
V.s - Serositis - Polyserositis
VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
VIII.t VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.t - Vocal cord paresis/paralysis
IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)
IX.d IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.d - Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis)
IX.r IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.r - Myasthenia gravis - Myasthenic-like syndrome
IX.ab IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.ab - Guillain-Barré (or GB-like) syndrome (w/wo ARF)
IX.ac IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.ac - Myositis of the respiratory muscles (May lead to respiratory muscle paralysis)
X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRES syndrome - DRESS-like reaction
X.c X - Systemic/Distant conditions, syndromes and reactions
X.c - Capillary leak syndrome (CLS)
X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic/Distant conditions, syndromes and reactions
X.e - Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)
X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal)
X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)
X.h X - Systemic/Distant conditions, syndromes and reactions
X.h - Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
X.j X - Systemic/Distant conditions, syndromes and reactions
X.j - Myopathy-Myositis-Polymyositis (see also under Xba)
X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic)
X.m X - Systemic/Distant conditions, syndromes and reactions
X.m - Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)
X.s X - Systemic/Distant conditions, syndromes and reactions
X.s - Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive
X.u X - Systemic/Distant conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
X.am X - Systemic/Distant conditions, syndromes and reactions
X.am - Immune-related adverse effect/toxicity
X.an X - Systemic/Distant conditions, syndromes and reactions
X.an - Cytokine release syndrome - Cytokine storm
X.aw X - Systemic/Distant conditions, syndromes and reactions
X.aw - Connective tissue disease
X.ay X - Systemic/Distant conditions, syndromes and reactions
X.ay - Polymyalgia rheumatica
XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis)
XI.y XI - Miscellaneous
XI.y - Adrenal suppression
XI.ag XI - Miscellaneous
XI.ag - Vertebral compression fracture
XI.au XI - Miscellaneous
XI.au - Graft vs. host disease in transplant recipients
XI.av XI - Miscellaneous
XI.av - Deterioration of graft function in SOT recipients
XI.ba XI - Miscellaneous
XI.ba - Nonrespiratory AE of interest
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade)
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis (can be fulminant)
XII.e XII - Cardiovascular involvement / toxicity
XII.e - Takotsubo (stress) cardiomyopathy
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.n XII - Cardiovascular involvement / toxicity
XII.n - Cardiovascular collapse - Cardiogenic shock - Hypotension
XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-)
XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity
XII.ax XII - Cardiovascular involvement / toxicity
XII.ax - Necrotizing myocarditis (w/o evidence for CAD)
XII.ba XII - Cardiovascular involvement / toxicity
XII.ba - Sudden cardiac death
XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib)
XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.l XV - Pathology
XV.l - Path: Pulmonary fibrosis (not otherwise specified or unclassifiable)
XV.v XV - Pathology
XV.v - Path: Micronodular organizing pneumonia/BOOP
XV.x XV - Pathology
XV.x - Path: Acute/subacute bronchiolitis (see also IVc, IVi)
XV.ba XV - Pathology
XV.ba - Path: Granulomatous lymphadenopathy
XV.co XV - Pathology
XV.co - Path: Foamy inclusions in alveolar macrophages and/or in other lung cells
XV.cp XV - Pathology
XV.cp - Path: Pneumocyte vacuolization
XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation
XVI.v XVI - Imaging
XVI.v - Imaging: Centrilobular micronodules (can be diffuse)
XVI.bh XVI - Imaging
XVI.bh - Imaging: F18-PET scan positive lympadenopathy
XVI.bt XVI - Imaging
XVI.bt - Imaging: A subsolid lung nodule or nodules
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infections
XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo
XVII.q XVII - Infections & related conditions
XVII.q - Viral pneumonia
XVII.r XVII - Infections & related conditions
XVII.r - Fungal infection (pulmonary/extrapulmonary)
XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
XIX.b XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.b - BAL: An excess proportion of neutrophils
XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils
1

Mesalazine-Mesalamine-5-aminosalicylic acid-5-ASA

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
II.d II - Pulmonary edema - Acute lung injury - ARDS
II.d - Pulmonary edema, cardiogenic
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)
IV.j IV - Airway involvement
IV.j - Bronchiolitis (a clinical-imaging pattern suggestive of)
IV.k IV - Airway involvement
IV.k - Bronchiectasis
IV.ad IV - Airway involvement
IV.ad - Large airway inflammation - Tracheitis (w/wo tissue eosinophilia)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (May commpany ILDs)
V.b V - Pleural and/or pericardial involvement
V.b - Eosinophilic pleural effusion
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)
X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRES syndrome - DRESS-like reaction
X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade)
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis (can be fulminant)
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction
XII.h XII - Cardiovascular involvement / toxicity
XII.h - Eosinophilic myocarditis
XII.n XII - Cardiovascular involvement / toxicity
XII.n - Cardiovascular collapse - Cardiogenic shock - Hypotension
XII.q XII - Cardiovascular involvement / toxicity
XII.q - Pericarditis (see also under XIIc)
XII.bf XII - Cardiovascular involvement / toxicity
XII.bf - Myopericarditis (see under XIIc/d/g)
XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib)
XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.z XV - Pathology
XV.z - Path: Obliterative (constrictive) bronchiolitis (see also IVc, IVn)
XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing
XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation
XVI.ay XVI - Imaging
XVI.ay - Imaging: Asymmetrical, predominantly unilateral involvement
XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils
1

Nivolumab

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP)
I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary infiltrates/ILD
I.ad I - Interstitial/parenchymal lung disease
I.ad - Radiation recall pneumonitis
I.aj I - Interstitial/parenchymal lung disease
I.aj - Shrinking lung syndrome
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
II.d II - Pulmonary edema - Acute lung injury - ARDS
II.d - Pulmonary edema, cardiogenic
III.g III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.g - Bleeding/hemorrhage from/around preexisting lung tumor (Localized AH)
III.j III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.j - Anti-GBM-related pneumorenal syndrome and DAH (Goodpasture) or flare of
III.m III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.m - Coagulopathy
IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)
IV.n IV - Airway involvement
IV.n - Obstructive airway dysfunction (see also IVc, XVx)
IV.y IV - Airway involvement
IV.y - Eosinophilic airway disease (asthma, bronchitis, bronchiolitis)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (May commpany ILDs)
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)
VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension
VIII.t VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.t - Vocal cord paresis/paralysis
IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)
IX.d IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.d - Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis)
IX.h IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.h - Dyspnea, unexplained otherwise
IX.r IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.r - Myasthenia gravis - Myasthenic-like syndrome
IX.y IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.y - A flare or relapse of preexisting myasthenia gravis
IX.ab IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.ab - Guillain-Barré (or GB-like) syndrome (w/wo ARF)
X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRES syndrome - DRESS-like reaction
X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal)
X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)
X.j X - Systemic/Distant conditions, syndromes and reactions
X.j - Myopathy-Myositis-Polymyositis (see also under Xba)
X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic)
X.m X - Systemic/Distant conditions, syndromes and reactions
X.m - Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)
X.n X - Systemic/Distant conditions, syndromes and reactions
X.n - Tumor lysis syndrome (TLS)
X.s X - Systemic/Distant conditions, syndromes and reactions
X.s - Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive
X.u X - Systemic/Distant conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
X.ac X - Systemic/Distant conditions, syndromes and reactions
X.ac - Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS)
X.ay X - Systemic/Distant conditions, syndromes and reactions
X.ay - Polymyalgia rheumatica
XI.i XI - Miscellaneous
XI.i - Esophageal toxicity
XI.av XI - Miscellaneous
XI.av - Deterioration of graft function in SOT recipients
XI.ax XI - Miscellaneous
XI.ax - Esophageal stenosis/stricture
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade)
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis (can be fulminant)
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction
XII.n XII - Cardiovascular involvement / toxicity
XII.n - Cardiovascular collapse - Cardiogenic shock - Hypotension
XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-)
XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity
XII.ax XII - Cardiovascular involvement / toxicity
XII.ax - Necrotizing myocarditis (w/o evidence for CAD)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XV.g XV - Pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa)
XV.bb XV - Pathology
XV.bb - Path: Airway inflammation
XVI.i XVI - Imaging
XVI.i - Imaging: An area or areas of involvement with a recognizable anatomic distribution
XVI.v XVI - Imaging
XVI.v - Imaging: Centrilobular micronodules (can be diffuse)
XVI.w XVI - Imaging
XVI.w - Imaging: Lung nodule or nodules
XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)
XVI.af XVI - Imaging
XVI.af - Imaging: Lung cysts or bullae (see also XVI ah/bf)
XVI.ai XVI - Imaging
XVI.ai - Imaging: A 'tree-in-bud' pattern
XVII.a XVII - Infections & related conditions
XVII.a - Respiratory tract infection incl. pneumonia
XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo
XVII.aj XVII - Infections & related conditions
XVII.aj - Bordetella bronchiseptica pulmonary infection
XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
XIX.b XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.b - BAL: An excess proportion of neutrophils
XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils
1

Penicillamine

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH)
III.b III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.b - Pneumorenal syndrome (w/wo ANCAs)
III.d III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.d - Alveolar hemorrhage, diffuse (ANCA-positive/-related)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)
IV.n IV - Airway involvement
IV.n - Obstructive airway dysfunction (see also IVc, XVx)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (May commpany ILDs)
IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)
IX.r IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.r - Myasthenia gravis - Myasthenic-like syndrome
X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic/Distant conditions, syndromes and reactions
X.e - Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)
X.j X - Systemic/Distant conditions, syndromes and reactions
X.j - Myopathy-Myositis-Polymyositis (see also under Xba)
X.s X - Systemic/Distant conditions, syndromes and reactions
X.s - Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive
X.ac X - Systemic/Distant conditions, syndromes and reactions
X.ac - Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS)
XI.t XI - Miscellaneous
XI.t - Yellow nail syndrome
XV.z XV - Pathology
XV.z - Path: Obliterative (constrictive) bronchiolitis (see also IVc, IVn)
XVII.w XVII - Infections & related conditions
XVII.w - Hypogammaglobulinemia - Antibody deficiency
2

Rituximab

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.v I - Interstitial/parenchymal lung disease
I.v - Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence
II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
II.i II - Pulmonary edema - Acute lung injury - ARDS
II.i - Flash (fulminate) pulmonary edema
III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH)
III.c III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.c - Hemoptysis
IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)
IV.d IV - Airway involvement
IV.d - Cough (lone)
IV.f IV - Airway involvement
IV.f - Severe or catastrophic bronchospasm or asthma attack (can be fatal)
IV.j IV - Airway involvement
IV.j - Bronchiolitis (a clinical-imaging pattern suggestive of)
IV.k IV - Airway involvement
IV.k - Bronchiectasis
VII.g VII - Mediastinal involvement
VII.g - Hemomediastinum - Mediastinal hematoma
VIII.x VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.x - Opportunistic large airway infection (bacterial, fungal, viral)
IX.t IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.t - CNS involvement/dysfunction/damage
IX.ab IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.ab - Guillain-Barré (or GB-like) syndrome (w/wo ARF)
X.b X - Systemic/Distant conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome
X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal)
X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)
X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic)
X.n X - Systemic/Distant conditions, syndromes and reactions
X.n - Tumor lysis syndrome (TLS)
X.s X - Systemic/Distant conditions, syndromes and reactions
X.s - Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive
X.ao X - Systemic/Distant conditions, syndromes and reactions
X.ao - Flare of preexisting vasculitis
XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis)
XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic)
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.j XV - Pathology
XV.j - Path: Pulmonary fibrosis (UIP-pattern)
XVII.a XVII - Infections & related conditions
XVII.a - Respiratory tract infection incl. pneumonia
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infections
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo
XVII.m XVII - Infections & related conditions
XVII.m - Fungal airway infection
XVII.q XVII - Infections & related conditions
XVII.q - Viral pneumonia
XVII.w XVII - Infections & related conditions
XVII.w - Hypogammaglobulinemia - Antibody deficiency
XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
XXI.c XXI - Rechallenge data
XXI.c - Tolerance can be induced successfully starting with minute dosage of the drug
1

Status post-hematopoietic stem cell (HSCT) or bone marrow transplantation (BMT)

I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.n I - Interstitial/parenchymal lung disease
I.n - Pulmonary alveolar proteinosis (PAP)
I.v I - Interstitial/parenchymal lung disease
I.v - Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence
I.x I - Interstitial/parenchymal lung disease
I.x - Pleuroparenchymal fibroelastosis (PPFE)
II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.e II - Pulmonary edema - Acute lung injury - ARDS
II.e - Transfusion-related acute lung injury (TRALI) (May cause ARDS)
II.n II - Pulmonary edema - Acute lung injury - ARDS
II.n - Engraftment syndrome
III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH)
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)
IV.m IV - Airway involvement
IV.m - Bronchial stenosis/stricture
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension
X.c X - Systemic/Distant conditions, syndromes and reactions
X.c - Capillary leak syndrome (CLS)
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure
XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.g XV - Pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa)
XV.ak XV - Pathology
XV.ak - Path: Pulmonary veno-occlusive disease (PVOD)
XV.ap XV - Pathology
XV.ap - Path: Pleuroparenchymal fibrosis/fibroelastosis (PPFE)
XV.bv XV - Pathology
XV.bv - Path: Pulmonary cytolytic thrombi
XVI.w XVI - Imaging
XVI.w - Imaging: Lung nodule or nodules
XVII.m XVII - Infections & related conditions
XVII.m - Fungal airway infection
5

Talc (inhaled, sniffed, i.v., intrapleural)

I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.t I - Interstitial/parenchymal lung disease
I.t - Pneumoconiosis (silicosis, talcosis...)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
II.f II - Pulmonary edema - Acute lung injury - ARDS
II.f - Hypoxemia, low oxygen saturation (may occur in isolation)
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)
IV.i IV - Airway involvement
IV.i - Foreign body aspiration bronchiolitis
IV.m IV - Airway involvement
IV.m - Bronchial stenosis/stricture
V.c V - Pleural and/or pericardial involvement
V.c - Pleural thickening
V.r V - Pleural and/or pericardial involvement
V.r - Pleural mass or masses
VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension
VI.g VI - Pulmonary vasculopathies
VI.g - Foreign body pulmonary vasculopathy (Excipient lung disease)
VII.f VII - Mediastinal involvement
VII.f - An enlarged or dense thymus
VII.n VII - Mediastinal involvement
VII.n - Mediastinal talcoma
X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal)
XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent
XI.u XI - Miscellaneous
XI.u - Chest pressure/discomfort
XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.q XV - Pathology
XV.q - Path: Foreign body deposits/granulomatous reaction
XV.s XV - Pathology
XV.s - Path: Pneumoconiosis (silicosis, talcosis, talcoma)
XV.ag XV - Pathology
XV.ag - Path: Foreign body embolism, microangiopathy, vasculopathy
XVI.w XVI - Imaging
XVI.w - Imaging: Lung nodule or nodules
XVI.ae XVI - Imaging
XVI.ae - Imaging: A pattern similar to pneumoconiotic progressive massive fibrosis (PMF)
XVI.bm XVI - Imaging
XVI.bm - Imaging: Avid pleural uptake on PET-scan
XVIII.i XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.i - Eye-catcher: Tracer-avid pleural area or areas on PET-CT
XIX.k XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.k - BAL: Talc crystals in macrophages or lying free in BALF
1

Vedolizumab

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)
VIII.aq VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.aq - Bronchorrhea
X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)
X.o X - Systemic/Distant conditions, syndromes and reactions
X.o - Neutrophilic dermatosis (Pyoderma, Sweet syndrome)
XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.x XV - Pathology
XV.x - Path: Acute/subacute bronchiolitis (see also IVc, IVi)
XV.cn XV - Pathology
XV.cn - Path: Pulmonary necrotizing granuloma with neutrophilic microabscesses
XVI.g XVI - Imaging
XVI.g - Imaging: Diffuse whiteout/alveolar shadowing (see also under IIb-ARDS)
XVI.v XVI - Imaging
XVI.v - Imaging: Centrilobular micronodules (can be diffuse)
XVII.a XVII - Infections & related conditions
XVII.a - Respiratory tract infection incl. pneumonia
XVII.v XVII - Infections & related conditions
XVII.v - Strongyloides stercoralis hyperinfection (w/wo DAH)
1